Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suneil Jain

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
The New England Journal of Medicine|October 16, 2024
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate CancerNicholas van As, Clare Griffin, Alison Tree, et al.
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
European Journal of Cancer (Oxford, England : 1990)|May 10, 2024
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trialPasquale Rescigno, Nuria Porta, Laura Finneran, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
The Journal of Clinical Investigation|December 25, 2019
Genomics of lethal prostate cancer at diagnosis and castration resistanceJoaquin Mateo, George Seed, Claudia Bertan, et al.
Ebiomedicine|May 7, 2018
Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate CancerLingjian Yang, Darren Roberts, Mandeep Takhar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 16, 2020
Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO GuidelineEdouard J Trabulsi, R Bryan Rumble, Hossein Jadvar, et al.
The Lancet. Oncology|December 7, 2019
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquin Mateo, Nuria Porta, Diletta Bianchini, et al.
European Urology|March 9, 2020
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic ReviewLisa Moris, Marcus G Cumberbatch, Thomas Van den Broeck, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
The New England Journal of Medicine|October 16, 2024
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate CancerNicholas van As, Clare Griffin, Alison Tree, et al.
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
European Journal of Cancer (Oxford, England : 1990)|May 10, 2024
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trialPasquale Rescigno, Nuria Porta, Laura Finneran, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
The Journal of Clinical Investigation|December 25, 2019
Genomics of lethal prostate cancer at diagnosis and castration resistanceJoaquin Mateo, George Seed, Claudia Bertan, et al.
Ebiomedicine|May 7, 2018
Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate CancerLingjian Yang, Darren Roberts, Mandeep Takhar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 16, 2020
Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO GuidelineEdouard J Trabulsi, R Bryan Rumble, Hossein Jadvar, et al.
The Lancet. Oncology|December 7, 2019
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquin Mateo, Nuria Porta, Diletta Bianchini, et al.
European Urology|March 9, 2020
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic ReviewLisa Moris, Marcus G Cumberbatch, Thomas Van den Broeck, et al.
Pageof 10